Quest Diagnostics
Provides clinical testing, pathology, and laboratory services through a North American network.
Something off on this page? Send us feedback.
Profile
Provides routine and advanced clinical laboratory testing, anatomic pathology, hospital reference testing, and hospital lab-management services, while ExamOne and Quanum serve insurers and healthcare organizations. Almost all revenue comes from Diagnostic Information Services, centered on a U.S. collection-and-testing network with an expanded Canadian presence through LifeLabs.
Provides routine, non-routine, and advanced clinical laboratory testing across oncology, genetics, brain health, and other specialties; anatomic pathology; hospital reference testing; and Collaborative Lab Solutions. Physicians, hospitals, and patients use a network of laboratories, patient service centers, couriers, mobile phlebotomists, and MyQuest access; ExamOne risk assessment and Quanum healthcare IT form the smaller Diagnostic Solutions group. Substantially all business is conducted in the United States, with LifeLabs extending the collection-and-testing network across parts of Canada.
Scale supports a broad test menu, specimen logistics, hospital partnerships, and data-enabled workflows. Almost all revenue comes from Diagnostic Information Services, primarily through fee-for-service testing billed to clients, patients, and third-party payers. Operations depend on physician referrals, health-plan access, reimbursement rules, accurate billing, healthcare regulation, data security, and consistent laboratory quality.
Company facts
Categories
Key statistics
Year to date +39.7% · Average volume (30d) 988.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 29, 2026 | Argus Research | Target | $260 | ||
| Jul 24, 2026 | UBS | Reiterate | Neutral | $210 | $232 |
| Jul 24, 2026 | Robert W. Baird | Target | $236 | $255 | |
| Jul 23, 2026 | Barclays | Reiterate | Overweight | $210 | $250 |
| Jul 23, 2026 | Jefferies | Reiterate | Buy | $225 | $245 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 23, 2026Q2 FY26 | $2.82 | $3.12 | +10.6% | $2.97B | $3.04B | +2.4% | −0.02% |
| Apr 21, 2026Q1 FY26 | $2.37 | $2.50 | +5.5% | $2.83B | $2.90B | +2.3% | −0.51% |
| Feb 10, 2026Q4 FY25 | $2.36 | $2.42 | +2.5% | $2.75B | $2.81B | +1.9% | +1.93% |
| Oct 21, 2025Q3 FY25 | $2.50 | $2.60 | +4.0% | $2.74B | $2.82B | +2.9% | −1.88% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.65B | $2.76B | $2.82B | $2.81B | $2.90B | $3.04B | |
| Gross profit | $863.0M | $943.0M | $949.0M | $914.0M | $942.0M | $1.03B | |
| Operating income | $346.0M | $438.0M | $386.0M | $391.0M | $399.0M | $459.0M | |
| Net income | $220.0M | $282.0M | $245.0M | $245.0M | $252.0M | $320.0M | |
| Diluted EPS | $1.94 | $2.47 | $2.16 | $2.18 | $2.24 | $2.84 | |
| Gross margin | 32.5% | 34.2% | 33.7% | 32.6% | 32.5% | 33.7% | |
| Operating margin | 13.0% | 15.9% | 13.7% | 13.9% | 13.8% | 15.1% |
Fiscal years (4-quarter sums)FY21 $10.79B · FY22 $9.88B · FY23 $9.25B · FY24 $9.87B · FY25 $11.04B
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $626.0M · Total debt $6.38B · Total assets $16.94B · Shareholders' equity $7.52B
Dividends
Raised for 21 straight years — most recently to $0.86 from $0.80 in Apr 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 8, 2026 | Jul 8 | Jul 22 | $0.86 | |
| Apr 6, 2026 | Apr 6 | Apr 20 | $0.86 | raised from $0.80 |
| Jan 13, 2026 | Jan 13 | Jan 28 | $0.80 | |
| Oct 3, 2025 | Oct 3 | Oct 20 | $0.80 | |
| Jul 7, 2025 | Jul 7 | Jul 21 | $0.80 | |
| Apr 7, 2025 | Apr 7 | Apr 21 | $0.80 | raised from $0.75 |
| Jan 14, 2025 | Jan 14 | Jan 29 | $0.75 | |
| Oct 4, 2024 | Oct 4 | Oct 21 | $0.75 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 110.37M · Float 109.84M · 99.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.28M | 8.40% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 7.23M | 6.55% | 13F | Aug 13, 2026 |
| T. Rowe Price Associates, Inc. | 7.21M | 6.50% | 13G | Aug 14, 2025 |
| Vanguard Portfolio Management LLC | 6.13M | 5.55% | 13F | Aug 13, 2026 |
| State Street Corp | 5.52M | 5.00% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 28, 2026 | Mark E. Delaney | officer: SVP & Chief Commercial Officer | −1,600 | $235.18 |
| Jun 4, 2026 | Karthik Kuppusamy | officer: SVP, Clinical Solutions | −8,147 | $200.00 |
| Jun 1, 2026 | J. E. Davis | director, officer: CEO and President | −10,000 | $194.14 |
| Mar 4, 2026 | Karthik Kuppusamy | officer: SVP, Clinical Solutions | −2,628 | $204.86 |
| Mar 5, 2026 | Patrick Plewman | officer: SVP for Diagnostic Services | −2,855 | $206.21 |
Peers
- Labcorp
National lab network with broad specialty-testing overlap
- Natera
cfDNA diagnostics across women's health and oncology MRD
- Guardant Health
Liquid biopsy, MRD, and colorectal screening overlap
- NeoGenomics
Cancer-focused labs with pathology and NGS overlap
- Myriad Genetics
Hereditary cancer, prenatal, and pharmacogenomics tests
- OPKO Health
Regional BioReference labs plus urology diagnostics
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Labcorp | $333.00 | −0.68% | $27.48B | 27.7 | 17.7 | 1.9 | +5.8% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Myriad Genetics | $3.16 | +0.48% | $298.5M | — | — | 0.4 | −10.5% |
| OPKO Health | $1.46 | −1.68% | $1.10B | — | — | 1.9 | +4.3% |
| Median | 27.7 | 41.3 | 1.9 | +8.5% |